Metabolic and Pharmacokinetic Differentiation of STX209 and Racemic Baclofen in Humans

STX209 is an exploratory drug comprising the single, active R-enantiomer of baclofen which is in later stage clinical trials for the treatment of fragile x syndrome (FXS) and autism spectrum disorders (ASD). New clinical data in this article on the metabolism and pharmacokinetics of the R- and S-ena...

Full description

Bibliographic Details

Published in:	Metabolites
Main Authors:	Raymundo Sanchez-Ponce, Li-Quan Wang, Wei Lu, Jana von Hehn, Maryann Cherubini, Roger Rush
Format:	Article
Language:	English
Published:	MDPI AG 2012-09-01
Subjects:	pharmacokinetics baclofen R-baclofen metabolic differentiation
Online Access:	http://www.mdpi.com/2218-1989/2/3/596